Psilocybin is primarily used as an experimental treatment for depression, addiction, and end-of-life psychological distress. While it remains a controlled substance in most of the United States, the FDA granted it breakthrough therapy designation for treatment-resistant depression in 2018 and major depressive disorder in 2019, fast-tracking its path through clinical trials. Oregon and Colorado have already legalized it for supervised therapeutic use.
Treatment-Resistant Depression
The most advanced research on psilocybin centers on depression that hasn’t responded to conventional treatments. In an open-label trial published in the American Journal of Psychiatry, patients with severe treatment-resistant depression received a single dose of psilocybin. At three weeks, roughly 67% met the criteria for a meaningful response and about 42% were in full remission. At 12 weeks, 58% still showed significant improvement and 25% remained in remission. These are notable numbers for a population that, by definition, hadn’t improved on standard antidepressants.
The effect sizes in this trial were unusually large compared to typical antidepressant studies. Depression scores dropped significantly within the first week and stayed low through the three-month follow-up, all from a single dose rather than daily medication.
Alcohol and Tobacco Addiction
Psilocybin-assisted psychotherapy has shown promise for substance use disorders, particularly alcohol use disorder and tobacco dependence. A systematic review covering 16 studies found that people receiving psilocybin therapy had significantly fewer heavy drinking days and higher rates of abstinence from alcohol. Brain imaging in these studies showed a normalization of activity in regions associated with craving and reward.
For smoking cessation, the results have been even more striking. Studies have demonstrated high quit rates that persisted well beyond the treatment period. One consistent finding across addiction research is that the intensity of the “mystical experience” during the psilocybin session predicted better long-term outcomes, suggesting the psychological shift matters as much as the pharmacology. Results for opioid dependence are more preliminary, with some signs of benefit but not yet enough data to draw firm conclusions.
Cancer-Related Anxiety and End-of-Life Distress
Psilocybin has been studied as a way to ease the existential anxiety and depression that often accompany a terminal diagnosis. Research at Johns Hopkins and other institutions has explored how psilocybin, combined with cognitive behavioral therapy, can reduce anxiety in cancer patients. Many participants in these trials described a fundamental shift in their relationship to death, moving from terror to a sense of acceptance or meaning. These psychological changes often lasted months after a single session.
How Psilocybin Works in the Brain
Psilocybin activates serotonin receptors in the brain, specifically a type called 5-HT2A. But recent research from UC Davis, published in Science, revealed something unexpected: the receptors that matter most aren’t on the surface of brain cells. They’re located inside the cell, in internal compartments. Psilocybin can slip through cell membranes to reach these interior receptors, which serotonin itself cannot easily do. This triggers a sustained growth signal that promotes the formation of new neural connections, increased branching of brain cells, and more connection points between neurons.
This structural rewiring helps explain why a single dose can produce lasting changes. Research from Washington University School of Medicine showed that psilocybin temporarily desynchronizes the default mode network, a set of brain areas that normally work together when your mind is wandering or ruminating. This network is overactive in depression, driving the kind of repetitive, self-focused negative thinking that characterizes the condition. By disrupting this pattern, psilocybin appears to create a window of flexibility where the brain can reorganize into healthier patterns of activity. The disruption is temporary, but the resulting flexibility can persist.
What a Therapeutic Session Looks Like
Psilocybin therapy isn’t just taking a pill. Clinical protocols involve three phases: preparation, dosing, and integration. Before the session, you meet with therapists to build trust, set intentions, and learn what to expect. The dosing session itself lasts roughly six to eight hours, during which you lie down in a comfortable setting, often with eyeshades and music, while one or two trained facilitators remain present. Doses in clinical trials typically range from 20 to 30 milligrams (adjusted for body weight), enough to produce a full psychedelic experience.
Afterward, you return for at least one integration session where you and your therapist work through the experience together, interpreting what came up and translating insights into lasting changes in thinking and behavior. The exact number of preparation and integration sessions varies. Some protocols include just a couple of meetings on either side of the dosing day, while others build in more extensive therapeutic support. This variability is one reason researchers are still working to standardize the approach.
Who Should Not Use Psilocybin
Psilocybin is not safe for everyone. According to UCSF’s psychedelic medicine program, it is contraindicated for people with a personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder. It can also be dangerous for anyone who experiences psychotic symptoms alongside depression. The risk in these cases is triggering a prolonged psychotic episode.
People with severe cardiovascular conditions, including uncontrolled blood pressure, heart failure, coronary artery disease, or a history of heart attack or stroke, should avoid psilocybin because it temporarily raises heart rate and blood pressure. Pregnancy and epilepsy are also exclusion criteria. If you take SSRI antidepressants or a type of older antidepressant called an MAO inhibitor, these medications interact with psilocybin and need to be tapered off before treatment, which itself carries risks.
People with significant trauma histories who haven’t yet developed fundamental coping skills or a safety plan should not use psilocybin, as the experience can surface overwhelming material without the psychological foundation to process it. Anyone who has previously had a severe adverse reaction to psychedelics, such as prolonged psychosis or suicidal thoughts, should not try again.
Legal Status in the United States
Psilocybin remains a Schedule I substance under federal law, meaning it’s classified as having no accepted medical use and a high potential for abuse. That classification exists in tension with the FDA’s own breakthrough therapy designations, which acknowledge its therapeutic potential.
Oregon was the first state to legalize psilocybin for supervised therapeutic use, and Colorado followed in 2023 when Governor Jared Polis signed legislation creating a regulated system of “healing centers” where adults over 21 can receive psilocybin under the guidance of a licensed facilitator. Colorado also allows individuals over 21 to cultivate psilocybin mushrooms at home in a locked space no larger than 12 by 12 feet, with no personal possession limit. Sharing with other adults is permitted in the context of counseling, spiritual guidance, or community-based support, but selling the mushrooms is not allowed. All regulated therapeutic sessions must use psilocybin sourced from licensed cultivators or manufacturers.
Several other cities and states have deprioritized enforcement of psilocybin possession laws or are considering their own regulatory frameworks, but Oregon and Colorado remain the only states with fully legalized therapeutic access.